SCHEMBL1349930

SCHEMBL1349930

c1ccc(C(c2ccccc2)c2nc3ccccc3[nH]2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.61
IDO1 P14902 1/20 0.61
POLB P06746 1/20 0.61
ALPL P05186 1/20 0.54
MAPK1 P28482 1/20 0.54
MLKL Q8NB16 3/20 0.53
GAA P10253 4/20 0.51
KMT2A Q03164 3/20 0.50
KDM4E B2RXH2 2/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
TAAR1 Q96RJ0 1/20 0.50
ABCB11 O95342 1/20 0.50
TP53 P04637 1/20 0.50
PKM P14618 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HSD17B10 Q99714 1/20 0.50
HPGD P15428 1/20 0.49
EGFR P00533 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11807688 0.81 ALDH1A1 (0.58) ALDH1A1IDO1POLBALPLMAPK1
SCHEMBL3397595 0.81 ALPL (0.58) ALDH1A1IDO1POLBALPLMAPK1
SCHEMBL11802373 0.81 ALDH1A1 (0.58) ALDH1A1IDO1POLBALPLMAPK1
SCHEMBL16756501 0.81 ALPL (0.58) ALDH1A1IDO1POLBALPLMAPK1
SCHEMBL899731 0.81 MLKL (0.77) ALDH1A1IDO1POLBALPLMAPK1
SCHEMBL16756243 0.81 ALPL (0.58) ALDH1A1IDO1POLBALPLMAPK1
SCHEMBL3397586 0.81 ALDH1A1 (0.62) ALDH1A1IDO1POLBALPLMAPK1
SCHEMBL30601597 0.81 MLKL (0.77) ALDH1A1IDO1POLBALPLMAPK1
SCHEMBL18689830 0.80 ALDH1A1 (0.62) ALDH1A1POLBMLKLGAAKMT2A
SCHEMBL7033890 0.80 MAPT (0.56) ALDH1A1POLBMAPK1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063090-B2 Mineralocorticoid receptor modulators MERCK SHARP & DOHME CORP. (US) 2011-11-22 US claimed
US-20100069452-A1 MINERALOCORTICOID RECEPTOR MODULATORS MERCK SHARP & DOHME CORP. 2010-03-18 US claimed
CN-106802536-B Transfer material, method for producing same, laminate, and method for producing same 富士胶片株式会社 2022-03-04 CN disclosed
CN-110716668-A Transfer film, laminate, method for producing same, and use thereof 富士胶片株式会社 2020-01-21 CN disclosed
US-10192651-B2 Transfer material, method of manufacturing transfer material, laminated body, method of manufacturing laminated body, method of manufacturing capacitance-type input device, and method of manufacturing image display device FUJIFILM CORPORATION (JP) 2019-01-29 US disclosed
US-10157695-B2 2018-12-18 US disclosed
US-10059087-B2 Transfer film, method for manufacturing transfer film, laminate, method for manufacturing laminate, capacitive input device, and image display device FUJIFILM CORPORATION (JP) 2018-08-28 US disclosed
CN-106802536-A Transfer materials and its manufacture method, layered product and its manufacture method 富士胶片株式会社 2017-06-06 CN disclosed
US-20170154704-A1 TRANSFER MATERIAL, METHOD OF MANUFACTURING TRANSFER MATERIAL, LAMINATED BODY, METHOD OF MANUFACTURING LAMINATED BODY, METHOD OF MANUFACTURING CAPACITANCE-TYPE INPUT DEVICE, AND METHOD OF MANUFACTURING IMAGE DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2017-06-01 US disclosed
CN-106660309-A Transfer film, method for manufacturing transfer film, laminate, method for manufacturing laminate, capacitance-type input device, and image display device 富士胶片株式会社 2017-05-10 CN disclosed
US-20170095999-A1 TRANSFER FILM, METHOD FOR MANUFACTURING TRANSFER FILM, LAMINATE, METHOD FOR MANUFACTURING LAMINATE, CAPACITIVE INPUT DEVICE, AND IMAGE DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2017-04-06 US disclosed
WO-1992007852-A1 BIPHENYLALKYL XANTHINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS G.D. SEARLE & CO. (US) 1992-05-14 WO disclosed
WO-1992005161-A1 1,3,5-TRISUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS G.D. SEARLE & CO. (US) 1992-04-02 WO disclosed
US-5098920-A Hypotensive agents and treatment of congestive heart failure G. D. SEARLE & CO. (US) 1992-03-24 US disclosed
WO-1992004335-A2 RENAL-SELECTIVE BIPHENYLALKYL 1H-SUBSTITUTED-1,2,4-TRIAZOLE ANGIOTENSIN II ANTAGONISTS FOR TREATMENT OF HYPERTENSION G.D. SEARLE & CO. (US) 1992-03-19 WO disclosed
WO-1992002257-A2 RENAL-SELECTIVE ANGIOTENSIN II ANTAGONISTS FOR TREATMENT OF HYPERTENSION G.D. SEARLE & CO. (US) 1992-02-20 WO disclosed
US-5087634-A N-substituted imidazol-2-one compounds for treatment of circulatory disorders G. D. SEARLE & CO. (US) 1992-02-11 US disclosed
WO-1991019715-A1 1H-SUBSTITUTED-IMIDAZO[4,5-d]PYRIDAZINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS G.D. SEARLE & CO. (US) 1991-12-26 WO disclosed
WO-1991018888-A1 N-SUBSTITUTED-1,2,4-TRIAZOLONE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS G.D. SEARLE & CO. (US) 1991-12-12 WO disclosed
WO-1991017148-A1 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS G.D. SEARLE & CO. (US) 1991-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069452-A1 MINERALOCORTICOID RECEPTOR MODULATORS NR3C2, MC2R, NR3C1 ALDH1A1 2362/4885IDO1 2516/4885POLB 4449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.